Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine

European Journal of Neuroscience

Volumn 14, Issue 9, 2001, Pages 1425-1435

  Petersén, Åsa ^a   Hansson, Oskar ^a,e   Puschban, Zoe ^a   Sapp, Ellen ^d   Romero, Norma ^b   Castilho, Roger F ^a   Sulzer, David ^b,c   Rice, Margaret ^e   DiFiglia, Marian ^d   Przedborski, Serge ^b   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell death; Huntington's disease; Oxidative stress; Striatum

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIOXIDANT; CYCLIC AMP; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRONE DERIVATIVE; OXIDOPAMINE; PHENYLBUTYL TERT NITRONE; PHOSPHOPROTEIN; SCAVENGER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AGE; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; ELECTRON MICROSCOPY; ENZYME INHIBITION; EXON; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MOLECULAR WEIGHT; MOUSE; MOUSE STRAIN; NEUROPIL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPIN TRAPPING; TRANSGENIC MOUSE;

AGING; ANIMALS; ASCORBIC ACID; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EXONS; GLUTATHIONE; HUNTINGTON DISEASE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; NEUROTOXINS; OXIDATIVE STRESS; OXIDOPAMINE; PHOSPHOPROTEINS; QUINOLINIC ACID; RETROGRADE DEGENERATION; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; URIC ACID;

EID: 0035783947     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-816X.2001.01765.x     Document Type: Article

References (55)

1. Asanuma, M., Hirata, H. & Cadet, J.L. (1998) Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions superoxide dismutase transgenic mice. Neuroscience, 85, 907-917.
2. Bibb, J.A., Snyder, G.L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A.A., Tsai, L.H., Kwon, Y.T., Girault, J.A., Czernik, A.J., Huganir, R.L., Hemmings, H.C., Nairn, A.C. & Greengard, P. (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature, 402, 669-671.
3. Bibb, J.A., Yan, Z., Svenningsson, P., Snyder, G.L., Pieribone, V.A., Horiuchi, A., Nairn, A.C., Messer, A. & Greengard, P. (2000) Severe deficiencies in dopamine signalling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA, 97, 6809-6814.
4. Campbell, K.M., McGrath, M.J. & Burton, F.H. (1999) Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists. Eur. J. Pharmacol., 37, 103-111.
5. Carter, R.J., Lione, L.A., Humby, T., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. & Morton, A.J. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci., 19, 3248-3257.
6. Cha, J.H., Frey, A.S., Alsdorf, S.A., Kerner, J.A., Kosinski, C.M., Mangiarini, L., Penney, J.B. Jr, Davies, S.W., Bates, G.P. & Young, A.B. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. Biol. Sci., 354, 981-989.
7. Cha, J.H., Kosinski, C.M., Kerner, J.A., Alsdorf, S.A., Mangiarini, L., Davies, S.W., Penney, J.B., Bates, G.P. & Young, A.B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. USA, 95, 6480-6485.
8. Chan, P., DiMonte, D.A., Langston, W.J. & Jansson, A.M. (1997) (+) MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J. Pharmacol. Exp. Therap., 280, 439-446.
9. Clarke, P.G.H. (1991) Developmental cell death: Morphological diversity and multiple mechanisms. Anat. Embryol., 181, 195-213.
10. Coyle, J.T. & Puttfarcken, P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science, 262, 689-695.
11. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. & Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-548.
12. van Dellen, A., Welch, J., Dixon, R.M., Cordery, P., York, D., Styles, P., Blakemore, C. & Hannan, A.J. (2000) N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport, 11, 3751-3757.
13. Ferger, B., Eberhardt, O., Teismann, P., de Groote, C. & Schulz, J.B. (1999) Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. J. Neurochem., 73, 1329-1332.
14. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A., O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D.C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.J., Hyman, S.E., Surmeier, D.J., Girault, J., Nestler, E.J. & Greengard, P. (1998) DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission. Science, 281, 838-842.
15. Filloux, F. & Townsend, J.J. (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol., 119, 79-88.
16. Gundersen, H.J.G., Bagger, P., Bendsten, B.F., Evans, S.M., Korbu, L., Marcussen, N., Moller, A., Nielsen, K., Nyengaard, J.R., Pakkenberg, B., Sorensen, F.B., Vesterby, A. & West, M.J. (1988) The new stereological tools: Dissector, fractionator, nucleator and point-sample intercepts and their use in pathological research and diagnosis. Acta Path. Microbiol. Immunol. Scand., 96, 857-881.
17. Hansson, O., Castilho, R.F., Korhonen, L., Lindholm, D., Bates, G.P. & Brundin, P. (2001) Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J. Neurochem., 78, 694-703.
18. Hansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R.F. & Brundin, P. (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA, 96, 8727-8732.
19. Hastings, T.G., Lewis, D.A. & Zigmond, M.J. (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA, 93, 1956-1961.
20. Hattori, A., Luo, Y., Umegaki, H., Munoz, J. & Roth, G.S. (1998) Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport, 9, 2569-2572.
21. Hickey, M.A. & Morton, A.J. (2000) Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J. Neurochem., 75, 2163-2171.
22. Iannicola, C., Moreno, S., Oliverio, S., Nardacci, R., Ciofi-Luzzatto, A. & Piacentini, M. (2000) Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J. Neurochem., 75, 830-839.
23. Jakel, R.J. & Maragos, W.F. (2000) Neuronal cell death in Huntington's disease: A potential role for dopamine. Trends Neurosci., 23, 239-245.
24. Kegel, K.M., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N. & DiFiglia, M. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci., 20, 7268-7268.
25. Kirik, D., Rosenblad, C. & Björklund, A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol., 152, 259-277.
26. Larsson, L.C., Czech, K.A., Widner, H. & Korsgren, O. (1999) Discordant neural tissue xenografts survive longer in immunoglobulin deficient mice. Transplantation, 68, 1153-1160.
27. Li, H., Li, S.H., Cheng, A.L., Mangiarini, L., Bates, G.P. & Li, X.J. (1999) Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet., 8, 1227-1236.
28. Lione, L.A., Carter, R.J., Hunt, M.J., Bates, G.P., Morton, A.J. & Dunnett, S.B. (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci., 19, 10428-10437.
29. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G., Ross, C.A., Borchelt, D.R., Tapscott, S.J., Young, A.B., Cha, J.H. & Olson, J.M. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
30. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. & Bates, G.P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
31. McLaughlin, B.A., Nelson, D., Erecinska, M. & Chesselet, M.F. (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor J. Neurochem., 70, 2406-2415.
32. Morton, A.J. & Leavens, W. (2000) Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res. Bull., 52, 51-59.
33. Murphy, K.P., Carter, R.J., Lione, L.A., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. & Morton, A.J. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci., 20, 5115-5123.
34. Nakao, N. & Brundin, P. (1998) Neurodegeneration and glutamate induced oxidative stress. Prog. Brain Res., 116, 245-263.
35. Nicniocaill, B., Haraldsson, B., Hansson, O., O'Connor, W.T. & Brundin, P. (2001) Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur. J. Neurosci., 13, 206-210.
36. Olney, J.W. & de Gubareff, T. (1978) Glutamate neurotoxicity and Huntington's chorea. Nature, 271, 557-559.
37. Perez-Severiano, F., Rios, C. & Segovia, J. (2000) Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res., 862, 234-237.
38. Petersén, Å., Larsen, K.E., Behr, G.G., Romero, N., Przedborski, S., Brundin, P. & Sulzer, D. (2001) Expanded CAG repeats in exon 1 of the Huntington's Disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet., 10, 1243-1254.
39. Petersén, Å., Mani, K. & Brundin, P. (1999) Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol., 157, 1-18.
40. Przedborski, S. & Jackson-Lewis, V. (1998) Experimental developments in movement disorders: Update on proposed free radical mechanisms. Curr. Opin. Neurol., 11, 335-339.
41. Przedborski, S. & Jackson-Lewis, V. (2000) ROS and Parkinson's disease: A view to a kill. In Poli, G., Cadenas, E. & Packer, L. (eds) Free Radicals in Brain Pathophysiology. Marcel Dekker, Inc., New York, pp. 273-290.
42. Rice, M.E., Lee, E.J. & Choy, Y. (1995) High levels of ascorbic acid, not glutathione, in the CNS of anoxia-tolerant reptiles contrasted with levels in anoxia-intolerant species. J. Neurochem., 64, 1790-1799.
43. Roizin, L., Stellar, S. & Liu, L.C. (1979) Neuronal nuclear-cytoplasmic changes in Huntington's chorea: Electron microscope investigations. Adv. Neurol., 23, 93-122.
44. Sapp, E., Penney, J., Young, A., Aronin, N., Vonsattel, J.P. & DiFiglia, M. (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in. Huntington disease. J. Neuropathol. Exp. Neurol., 58, 165-173.
45. Sauer, H. & Oertel, W.H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience, 59, 401-415.
46. 14C]2-deoxy-D-glucose autoradiography. J. Neurochem., 38, 737-748.
47. Schmued, L.C., Albertson, C. & Slikker, W. (1997) Fluoro-Jade: A novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res., 751, 37-46.
48. Schwartz, P.J., Reaume, A., Scott, R. & Coyle, J.T. (1998) Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Res., 789, 32-39.
49. Stokes, A.H., Hastings, T.G. & Vrana, K.E. (1999) Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res., 55, 659-665.
50. Sulzer, D. & Zecca, L. (2000) Intraneuronal dopamine-quinone synthesis: A review. Neurotox. Res., 1, 181-195.
51. Tabrizi, S.J., Workman, J., Hart, P.E., Mangiarini, L., Mahal, A., Bates, G., Cooper, J.M. & Schapira, A.H. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol., 47, 80-86.
52. Tellez-Nagel, I., Johnson, A.B. & Terry, R.D. (1975) Studies on brain biopsies of patients with Huntington's chorea. J. Neuropathol. Exp. Neurol., 33, 308-332.
53. Tøien, Ø., Drew, K.L., Chao, M.L. & Rice, M.E. (2001) Ascorbate dynamics and oxygen consumption during arousal from hibernation in arctic ground squirrels. Am. J. Physiol., in press.
54. Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G.P. & Davies, S.W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA, 97, 8093-8097.
55. Vonsattel, J.P. & DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.